The University of North Texas Health Science Center, commonly known as the UNT Health Science Center and abbreviated UNTHSC, is a graduate-level institution of the University of North Texas System. The 1,949-student, 33-acre campus opened in 1970 and is located in the Cultural District of Fort Worth, in the U.S. state of Texas.The UNT Health Science Center comprises the Texas College of Osteopathic Medicine , the Graduate School of Biomedical science, the School of Public Health, the School of Health Professions, the UNT System College of Pharmacy, plus other centers and institutes.UNT Health at UNTHSC is the TCOM faculty practice program providing direct patient care. UNT Health handles over 600,000 patient visits annually. The group's 170 physicians practice in 40 medical and surgical specialties and subspecialties, including allergy/immunology, family practice, cardiology, neurology, obstetrics & gynecology, oncology, orthopedics, psychiatry, sports medicine and neurosurgery.Research centers and institutes at UNTSHC include the Cardiovascular Research Institute , the Center for Commercialization of Fluorescence Technologies , the Focused on Resources for her Health Education and Research , the Institute for Aging and Alzheimer's Disease Research , the Institute for Cancer Research , the Institute of Applied Genetics , the North Texas Eye Research Institute , the Osteopathic Research Center , the Texas Prevention Institute , the Center For Community Health , the Primary Care Research Center , and The Texas Center for Health Disparities .The UNT Center for Human Identification, which is housed at UNTHSC, analyzes DNA samples from both unidentified remains as well as reference samples submitted by family members of missing persons to law enforcement agencies nationwide. It also conducts all DNA analysis for the National Center for Missing and Exploited Children. The Center is the only academic center in the U.S. with access to the FBI’s next-generation CODIS 6.0 DNA Software. UNTHSC also manages the National Missing and Unidentified Persons System for the U.S. Department of Justice.UNTHSC serves as home to several National Institutes of Health-funded research programs and currently leads all Texas health science centers in research growth. The Health Science Center also houses laboratories for TECH Fort Worth, a non-profit business incubator for biotechnology.Community and school outreach programs include Fort Worth’s annual Hispanic Wellness Fair and the annual Cowtown Marathon, which were founded by UNTHSC. The UNTHSC Pediatric Mobile Clinic provides high-quality healthcare to children in underserved areas of Fort Worth at no cost. The Health Science Center participates in 10 state and federally funded programs that bring students and teachers onto campus each summer. Wikipedia.
University of North Texas Health Science Center | Date: 2016-11-18
Described herein are nanoparticles comprising a mixture of a steroid, a phospholipid composition, an -tocopheryl compound, and a therapeutic agent wherein the -tocopheryl compound is presented on the surface of the nanoparticle. In some embodiments, the nanoparticles are useful for delivering a peptide or a protein. In some embodiments, the nanoparticles are formulated for ocular administration. In other embodiments, the nanoparticles are formulated to cross the blood brain barrier for the delivery of the therapeutic agents to the brain.
University of North Texas Health Science Center | Date: 2016-09-30
Pharmaceutical composition comprising a pharmaceutically acceptable oil phase, a surfactant, and a therapeutic agent are provided herein, wherein the composition is in the form of a pro-nanoparticle or a self-assembling nanoparticle. Additionally, these pharmaceutical compositions have high loading of the therapeutic agent. Also provided herein are methods of preparing the pharmaceutical compositions and methods using the compositions in the treatment of a patient.
Emmitte K.A.,University of North Texas Health Science Center
Expert Opinion on Therapeutic Patents | Year: 2017
Introduction: The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD. Areas covered: This review begins with an update of the clinical activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013. The summaries are organized into three separate sections: (1) inventions centered on improvements to existing clinical compounds; (2) new small molecules that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compounds; and (3) new small molecules that are not from a disubstituted alkyne chemotype. Expert opinion: It is a critical moment for mGlu5 NAM research as recent reports from clinical trials have included some significant disappointments that have blunted prior optimism. Still, research in this area remains active, and recent years have added several more attractive small molecules to this field. There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Uteshev V.V.,University of North Texas Health Science Center
Current Pharmaceutical Design | Year: 2016
Expressing functional nicotinic acetylcholine receptors (nAChRs) may be beneficial to central neurons and neuronal networks because activation of nAChRs enhances neuronal resistance to injury, improves attention, cognitive performance, and produces robust anti-inflammatory and analgesic effects in mammals. Although exogenous orthosteric nAChR ligands present valuable tools in treatment of age-and trauma-related neurological deficits, therapeutic approaches that could amplify the brain’s innate ability to maintain cholinergic homeostasis and resist injury may serve as intriguing and promising alternatives and have not been fully explored. One of these novel approaches utilizes positive allosteric modulators (PAMs) of nAChRs. Because of the ubiquitous expression of nAChRs in neuronal, glial and immune tissues, highly selective PAMs could amplify multiple endogenous neuroprotective, pro-cognitive, anti-inflammatory and anti-nociceptive cholinergic pathways to offset cholinergic hypofunction and generate therapeutic efficacy by targeting only a single player: i.e., nAChRs activated by endogenous cholinergic tone. In this article, I review the concept of allosteric modulation and current trends in therapeutic applications of nicotinic PAMs. © 2016 Bentham Science Publishers.
University of North Texas Health Science Center and Board Of Regents Of The University Of Texas System | Date: 2015-01-20
Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165(^(165)Ho) and dysprosium-164 (^(164)Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particle and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandages coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).
MacHu T.K.,University of North Texas Health Science Center
Pharmacology and Therapeutics | Year: 2011
The 5-Hydroxytryptamine3 (5-HT3) receptor is a member of the cys-loop family of ligand gated ion channels, of which the nicotinic acetylcholine receptor is the prototype. All other 5-HT receptors identified to date are metabotropic receptors. The 5-HT3 receptor is present in the central and peripheral nervous systems, as well as a number of non-nervous tissues. As an ion channel that is permeable to the cations, Na+, K+, and Ca2+, the 5-HT3 receptor mediates fast depolarizing responses in pre- and post-synaptic neurons. As such, 5-HT 3 receptor antagonists that are used clinically block afferent and efferent synaptic transmission. The most well established physiological roles of the 5-HT3 receptor are to coordinate emesis and regulate gastrointestinal motility. Currently marketed 5-HT3 receptor antagonists are indicated for the treatment of chemotherapy, radiation, and anesthesia-induced nausea and vomiting, as well as irritable bowel syndrome. Other therapeutic uses that have been explored include pain and drug addiction. The 5-HT3 receptor is one of a number of receptors that play a role in mediating nausea and vomiting, and as such, 5-HT3 receptor antagonists demonstrate the greatest anti-emetic efficacy when administered in combination with other drug classes. © 2011 Elsevier Inc.
Uteshev V.V.,University of North Texas Health Science Center
European Journal of Pharmacology | Year: 2014
In the central nervous system, deficits in cholinergic neurotransmission correlate with decreased attention and cognitive impairment, while stimulation of neuronal nicotinic acetylcholine receptors improves attention, cognitive performance and neuronal resistance to injury as well as produces robust analgesic and anti-inflammatory effects. The rational basis for the therapeutic use of orthosteric agonists and positive allosteric modulators (PAMs) of nicotinic receptors arises from the finding that functional nicotinic receptors are ubiquitously expressed in neuronal and non-neuronal tissues including brain regions highly vulnerable to traumatic and ischemic types of injury (e.g., cortex and hippocampus). Moreover, functional nicotinic receptors do not vanish in age-, disease- and trauma-related neuropathologies, but their expression and/or activation levels decline in a subunit- and brain region-specific manner. Therefore, augmenting the endogenous cholinergic tone by nicotinic agents is possible and may offset neurological impairments associated with cholinergic hypofunction. Importantly, because neuronal damage elevates extracellular levels of choline (a selective agonist of α7 nicotinic acetylcholine receptors) near the site of injury, α7-PAM-based treatments may augment pathology-activated α7-dependent auto-therapies where and when they are most needed (i.e., in the penumbra, post-injury). Thus, nicotinic-PAM-based treatments are expected to augment the endogenous cholinergic tone in a spatially and temporally restricted manner creating the potential for differential efficacy and improved safety as compared to exogenous orthosteric nicotinic agonists that activate nicotinic receptors indiscriminately. In this review, I will summarize the existing trends in therapeutic applications of nicotinic PAMs. © 2014 Elsevier B.V.
University of North Texas Health Science Center | Date: 2015-04-07
The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.
Agency: NSF | Branch: Standard Grant | Program: | Phase: Gen & Age Rel Disabilities Eng | Award Amount: 299.99K | Year: 2016
Cerebral Palsy (CP) is a birth related brain injury affecting functional activities of persons throughout the life span. Many children with CP have some form of upper extremity limitations. Reduced function of the hands hinder dressing, personal hygiene, and use of assistive devices, resulting in greater dependency, restricted social participation, and a decreased quality of life. Recent investigations have indicated that the brain is capable of reorganizing itself through targeted use. Functional recovery requires repeated practice, however traditional therapy sessions are inadequate in duration and intensity. Soft robotic devices show promise as a therapy extender needed for motor learning. No device has shown comprehensive capabilities to address this need in children, particularly a device that can provide continuous measurements and data monitoring, characterize the spastic resistance, and accommodate growth as needed. The soft-‐robotic glove, REHAB Glove, developed in this project will fill an important gap to improve independence and to reduce burden of care. The capabilities of this glove will not only address the therapy need of CP children but will also act as an important tool for data gathering for the development of dosage based therapy regimes for better outcomes. The proposed research will also serve as a training ground for medical and engineering students to become competent researchers as they will have the opportunity to join the project team for internships, mentorships, job shadowing, enrichment programs or summer academy.
Current hand rehabilitation devices, based on end-‐effector and hard exoskeleton structures, are complex, have limited degrees of freedom, and are mostly applicable to only four fingers of the hand. All of these factors limit their capacity to support complex hand rehabilitation. Furthermore, the widespread usage of these systems in home environments is hindered by their mechanical complexity, cost, and potential safety concerns. Recent advances in soft robotics using flexible structures and actuators are being explored to reduce the complexity of these devices and improve human-‐robotic interaction. In this work, a sensorized soft robotic glove will be developed using novel soft-‐and-‐rigid hybrid actuators alongside an advanced control unit with closed-‐loop control. The PIs postulate that using a sensorized therapeutic glove capable of monitoring and assisting patient hand motion will enable children with CP to complete repetitive motions, and that children and parents can accept the robotic glove as a tool to optimize their rehabilitation. This device will help reduce the complexity, size, and cost associated with current state-of-the-art care as well as enable the development of dosage based therapy studies. The soft robotic glove is made of compliant elastomeric material, which provides a safe user-device interaction and allows customized fitting onto hands with different conditions and sizes. Sensor integration will provide the capability to monitor and record hand motion and thus evaluate the rehabilitation progress and facilitate clinical research of the hand. With an associated control unit, the device can be portable and used at home or in the hospital. This project leverages a unique collaboration that brings cutting-edge engineering, therapy, and clinical knowledge to the development of an efficacious assistive technology that can be used to facilitate recovery of hand function. The goals of this project will be accomplished by executing the following aims: 1) Develop a soft robotic glove for children with integrated sensors that measure finger trajectory and force; 2) Develop a control algorithm to assist hand motion in different operation modes; 3) Test and validate the systems ability to measure finger motion parameters; 4) Obtain feedback from children, parents, rehabilitation physicians and therapists regarding the ease of use of the REHAB Glove, and their desire to use the tool in their daily rehab practice and exercise.
University of North Texas Health Science Center | Date: 2015-05-29
The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.